Investor
Pfizer Inc
CIK 0000078003 · filed 2026-05-12 · SEC filing
13F book
$238.8M
Positions
18
1 new · 1 sold
Largest name
24.1%
Oric Pharmaceuticals, Inc. · ORIC
Est. mark
$13.9M
Price effect on 17 names still held. Flow −$11.6M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Oric Pharmaceuticals, Inc. | ORIC | 4.78M | $57.7M | 24.1% | $18.5M | Cut$13.7M |
| Allogene Therapeutics, Inc. | ALLO | 22M | $49.8M | 20.9% | $19.6M | Held |
| Arvinas, Inc. | ARVN | 3.46M | $34.9M | 14.6% | −$6.09M | Held |
| Celcuity Inc. | CELC | 295.7K | $31.3M | 13.1% | $1.86M | Cut−$3.5M |
| Zura Bio Ltd | ZURA | 2.84M | $16.8M | 7.0% | $1.96M | Cut$1.27M |
| Wave Life Sciences Ltd. | WVE | 1.88M | $11.9M | 5.0% | −$19.9M | Held |
| Pyxis Oncology, Inc. | PYXS | 7.03M | $9.21M | 3.9% | $1.13M | Held |
| Caribou Biosciences, Inc. | CRBU | 4.69M | $8.35M | 3.5% | $891.2K | Held |
| Spero Therapeutics, Inc. | SPRO | 2.36M | $5.5M | 2.3% | $0 | Held |
| Biohaven Ltd. | BHVN | 505.6K | $4.23M | 1.8% | −$1.48M | Held |
| Cardiff Oncology, Inc. | CRDF | 2.41M | $3.74M | 1.6% | −$3.04M | Held |
| Zentalis Pharmaceuticals, Inc. | ZNTL | 953.8K | $2M | 0.8% | $715.4K | Held |
| NextCure, Inc. | NXTC | 153.4K | $1.54M | 0.6% | −$641K | Cut−$701.9K |
| Agomab Therapeutics Nv | AGMB | 75K | $813.8K | 0.3% | — | New |
| Q32 Bio Inc. | QTTB | 101.6K | $736.7K | 0.3% | $399.4K | Cut−$185.5K |
| Bolt Biotherapeutics, Inc. | BOLT | 31.3K | $137.1K | 0.1% | −$34.1K | Held |
| Ginkgo Bioworks Holdings Inc | — | 2.93K | $17.4K | 0.0% | −$6.97K | Held |
| Senseonics Hldgs Inc | — | 2.17K | $14.2K | 0.0% | $2.26K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.